Vanguard Fiduciary Trust
KAPA

Vanguard Fiduciary Trust’s Kairos Pharma KAPA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Hold
63,884
– – ﹤0.01% 3972
2026
Q1 		$35.7K Buy
+63,884
New +$42.8K ﹤0.01% 3879

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Fiduciary Trust's KAPA Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Kairos Pharma (KAPA) position steady in Q2 2026 at 63,884 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3972.

Vanguard Fiduciary Trust first reported a position in KAPA in Q1 2026 and has held it in 2 quarters since. The position peaked at $35.7K in Q1 2026. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Vanguard Fiduciary Trust held 63,884 shares of Kairos Pharma worth $24.5K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Kairos Pharma share count unchanged in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3972 holding.
  • Vanguard Fiduciary Trust first reported a position in Kairos Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Kairos Pharma position peaked at $35.7K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.